Oncology reigns over Pfizer's latest pipeline
This article was originally published in Scrip
Executive Summary
Pfizer's decision to move away from cardiovasculars and focus on cancer, diabetes and neurologicals merely confirms a trend that has been apparent in its early-stage pipeline for some time.